Osaka, Japan

Akira Ino

This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Shionogi Company Limited. Active years: 2000-2018.


% Patents Active = 25.0

 

 

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Koka-gun, JP (2000)
  • Osaka, JP (2015 - 2018)

Company Filing History:


Years Active: 2000-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Akira Ino: Innovator in AMPK-Activating Compounds

Introduction

Akira Ino is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that activate AMP-activated protein kinase (AMPK). With a total of 4 patents to his name, Ino's work is paving the way for advancements in metabolic health.

Latest Patents

One of Ino's latest patents includes an azabenzimidazole derivative that exhibits AMPK-activating activity. This compound is disclosed as being useful as an AMPK activator, which has potential implications for treating various metabolic disorders. The patent details a compound represented by a specific formula, or a pharmaceutically acceptable salt thereof, that can enhance AMPK activity.

Career Highlights

Ino is currently employed at Shionogi & Company Limited, a well-respected pharmaceutical company known for its innovative research and development. His work at Shionogi has allowed him to focus on creating effective therapeutic solutions that address critical health issues.

Collaborations

Ino has collaborated with notable colleagues, including Eiichi Kojima and Keisuke Tonogaki. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to groundbreaking discoveries in the pharmaceutical field.

Conclusion

Akira Ino's contributions to the field of AMPK-activating compounds highlight his innovative spirit and dedication to improving health outcomes. His work continues to inspire advancements in pharmaceutical research and development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…